Premium
Levodopa‐entacapone‐carbidopa intestinal gel in Parkinson's disease: A randomized crossover study
Author(s) -
Senek Marina,
Nielsen Elisabet I.,
Nyholm Dag
Publication year - 2017
Publication title -
movement disorders
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 3.352
H-Index - 198
eISSN - 1531-8257
pISSN - 0885-3185
DOI - 10.1002/mds.26855
Subject(s) - entacapone , levodopa , carbidopa , crossover study , parkinson's disease , medicine , gastroenterology , catechol o methyl transferase , randomized controlled trial , pharmacology , chemistry , disease , placebo , pathology , allele , biochemistry , alternative medicine , gene
Background The addition of oral entacapone to levodopa‐carbidopa intestinal gel treatment leads to less conversion of levodopa to 3‐O‐methyldopa, thereby increasing levodopa plasma concentration. The objective of this study was to compare systemic levodopa exposure of the newly developed levodopa‐entacapone‐carbidopa intestinal gel after a 20% dose reduction with levodopa exposure after the usual levodopa‐carbidopa intestinal gel dose in a randomized crossover trial in advanced Parkinson's disease patients. Methods In this 48‐hour study, 11 patients treated with levodopa‐carbidopa intestinal gel were randomized to a treatment sequence. Blood samples were drawn at prespecified times, and patient motor function was assessed according to the treatment response scale. Results Systemic exposure of levodopa did not differ significantly between treatments (ratio, 1.10 [95% confidence interval, 0.951‐1.17]). Treatment response scale scores did not significantly differ between treatments ( P = 0.84). Conclusions Levodopa‐entacapone‐carbidopa intestinal gel allowed a lower amount of levodopa administration and was well tolerated. Long‐term studies are needed to confirm the results. © 2016 International Parkinson and Movement Disorder Society.